Allogeneic γδT Cells in Glioblastoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-70
SponsorPeking University Third Hospital
About this trial
This first-in-human clinical study aims to evaluate the safety and feasibility of locally delivered, allogeneic γδ T cells (genetically edited with ARIH1 and BCL11b knockout, designated ABOUT γδT cells) in patients with glioblastoma multiforme (GBM). The engineered effector cells are delivered via localized administration to selectively target and eliminate residual GBM cells. ABOUT: ARIH1 and BCL11b knockOUT γδ T cells.
Eligibility criteria
Qualifiers
Male or female, age 18-70 years old (both ends included)
At least one evaluable lesion with previous biopsy or pathohistologic confirmation of glioblastoma (WHO grade IV), with imaging suggestive of continued progression or recurrence after comprehensive treatment
Karnofsky Performance Status (KPS) ≥ 60%
Life expectancy > 4 weeks
Disqualifiers
Active hepatitis B or C virus, HIV infection, or other untreated active infection
Pregnant and lactating women
Participants with organ failure
Participants with a chronic disease requiring immunologic or hormonal therapy
Trial design
Treatments tested in this trial
- Allogeneic γδ T (ABOUT) cells
Treatment groups
18 Participants
are divided into 3 treatment groupsLocations
3Peking University Third Hospital100191, BeijingBeijing Municipality, China
Henan Academy of Innovations in Medical Science451162, ZhengzhouHenan, China
Zhengzhou Second Hospital450052, ZhengzhouHenan, China
Sponsors and collaborators
Peking University Third Hospital
Lead sponsor
Peking University
Collaborator
Changping Laboratory
Collaborator
Source ClinicalTrials.gov